UltraSound - Technology Information PortalWednesday, 8 September 2010
Info
  Sheets



Out-
      side
 




 
 'Filling Gas' 
SEARCH FOR    
 
  1 2 3 4 5 A B C D E F G H I J K L M N O P Q R S T U V W Z
Result : Searchterm 'Filling Gas' found in 1 term [] and 8 definitions [], (+ 15 Boolean[] results)
1 - 5 (of 24)     next
Result Pages : [1]  [2]  [3 4 5]
 bottom
US Resources  
UltraSound Technician and Technologist Career - DICOM - Breast - Non-English - Pediatric - Doppler UltraSound
 
Filling GasInfoSheet: - Contrast Agents - Intro, Historical Development, Microbubbles, etc.MRI Resource Directory: - Contrast Agents -
 
The gas in microbubbles is highly compressible and, when subjected to the alternating compression and refraction pressures that constitute an ultrasound pulse, microbubbles oscillate at their natural frequency at which they resonate most strongly. This is determined by their size but is also influenced by the composition of the filling gas.
Air, sulfur hexafluoride, nitrogen, and perfluorochemicals are used as filling gases. Most newer ultrasound contrast agents use perfluorochemicals because of their low solubility in blood and high vapor pressure. By substituting different types of perfluorocarbon gases for air, the stability and plasma longevity of the agents have been markedly improved, usually lasting more than five minutes.
spacer
Acoustically Active LipospheresMRI Resource Directory: - Contrast Agents -
 
(AALs) Acoustically active lipospheres and ultrasound are under development to deliver bioactive molecules to the vascular endothelium. The AALs are similar to both ultrasound contrast agents and drug-delivering liposomes. They can carry bioactive substances using biologically inert shells and deliver those substances when disrupted by ultrasound.
The lipospheres consist of a small gas microbubble surrounded by a thick oil shell and are enclosed by an outermost lipid layer. The gas bubble contained in these vehicles makes them acoustically active, similar to ultrasound contrast agents. Acoustically active lipospheres can be nondestructively deflected using ultrasound radiation force, and fragmented with high intensity ultrasound pulses. Their lipid-oil complex can carry bioactive substances at high concentrations. An optimized sequence of ultrasound pulses can deflect the AALs toward a vessel wall then disrupt them, painting their contents across the vascular endothelium.
See also Filling Gas, and MRX 115.
spacer
 Further Reading:
  Basics:
A Method for Radiation-Force Localized DrugDelivery Using Gas-Filled Lipospheres(.pdf)Open this link in a new window
Wednesday, 7 July 2004   by www.ncbi.nlm.nih.gov    
  News & More:
Radiation-Force Assisted Targeting Facilitates Ultrasonic Molecular ImagingOpen this link in a new window
Sunday, 4 July 2004   by www.bme.ucdavis.edu    
Bio-effects of ultrasound contrast agents in daily clinical practice: fact or fiction?(.pdf)Open this link in a new window
Monday, 30 April 2007   by eurheartj.oxfordjournals.or    
US Resources  
Renal - Gall Bladder - Ultrasound Guided Interventions - Image Quality - Education pool - Vascular
 
AI-700InfoSheet: - Contrast Agents - Intro, Historical Development, Microbubbles, etc.MRI Resource Directory: - Contrast Agents -
 
From Acusphere Inc
AI-700 is an US contrast agent, usable for myocardial perfusion undergoing regulatory FDA approval. The synthetic polymers used in AI-700 do not break during the ultrasound imaging procedure. The used perfluorocarbon filling gas is less soluble in water and therefore has the propensity to stay inside the contrast agent particles. As a result, a higher concentration of gas is delivered to the myocardium over a longer period of time, thereby enabling AI-700 to target the broader application of myocardial perfusion assessment.
AI-700 is a dry powder consisting of small, porous microparticles filled with perfluoropropane. These microparticles are made of a synthetic biodegradable polymer, called poly (D, L-lactide co-glycolide), or PLGA, that has been used in other drug delivery systems approved by the FDA.
The composition and structure of the phospholipid containing microparticles and the properties of the perfluorocarbon gas slow the rate at which the gas dissolves and prevent the microparticles from being quickly broken down. The powder is to suspend in sterile water and injected by a single intravenous injection prior to ultrasound imaging.

In June 2004, Acusphere entered into a Collaboration, License and Supply Agreement with Nycomed Danmark APS for the European development and marketing rights to Acusphere’s lead product candidate AI-700.
Nycomed will be responsible for sales, marketing and the regulatory submissions required for marketing throughout its sales territory, which includes the member states of the European Union, as well as Russia/CIS and the Baltic States.

Drug Information and Specification:
RESEARCH NAME AI 700
DEVELOPER Acusphere, Inc.
INDICATION -
DEVELOPMENT STAGE		 myocardial perfusion
APPLICATION Intravenous injection
TYPE Microbubble
SHELL Poly-L-lactide co glycolide
CHARGE Negative
GAS Perfluorocarbon
MICROBUBBLE SIZE -
PREPARATION Reconstitute with water
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer
    ••    There are 3 news about 'AI-700'.
spacer
 Further Reading:
  Basics:
Acusphere Successfully Completes First Commercial Scale AI-700 Batch; Important Q2 Milestone AchievedOpen this link in a new window
Tuesday, 11 July 2006   by www.acusphere.com    
  News & More:
Acusphere's AI-700 Pilot Study Exceeds ExpectationsOpen this link in a new window
Thursday, 6 January 2005   by www.thefreelibrary.com    
Acusphere Reaches AI-700 Clinical Trial Milestone; 300 Patients Enrolled in Phase 3 Clinical ProgramOpen this link in a new window
Thursday, 16 December 2004   by phx.corporate-ir.net    
A Method for Radiation-Force Localized DrugDelivery Using Gas-Filled Lipospheres(.pdf)Open this link in a new window
Wednesday, 7 July 2004   by www.ncbi.nlm.nih.gov    
Acusphere Completes Enrollment in Second Phase 3 ClinicalOpen this link in a new window
Friday, 5 May 2006   by phx.corporate-ir.net    
Alliance Pharmaceutical Corp.MRI Resource Directory: - Manufacturers -
 
www.allp.htm

California-based research and development company. Alliance Pharmaceutical Corporation. The principal activities of the Company is identifying, designing, and developing novel medical products. The Company is engaged in development of scientific discoveries into medical products and licensing these products to multinational pharmaceutical companies in exchange for fixed payments and royalty or profit sharing payments. The Company has developed three innovative products through initial clinical (human) trials. The products are Oxygent™, Liquivent and Imavist™. The Company's strategy is to identify potential new medical products though its own efforts and scientific collaborations with researchers and clinicians in universities and medical centers. In Dec 2000 the company acquired Molecular Biosystems Inc a developer of intravenous ultrasound contrast agent for the heart.

"September 20, 2001 Alliance Pharmaceutical Corp. announced that it has won a favorable Final Judgment from the United States Patent and Trademark Office's Board of Patent Appeals and Interferences regarding claims in U.S. Patent No. 5,558,854, which is owned by Nycomed Imaging, AS. The Final Judgment determined that claims made in the Nycomed patent with respect to "microbubbles" that contain perfluorohexane filling gas are invalid and are therefore unpatentable."

Ultrasound Related Product Lines:
Contrast Agents:
TRADE NAME FOR SALE FOR SALE /
DEVELOPMENT		 DEVELOPMENT
Imagent®

Contact Information:
MAIL Alliance Pharmaceutical Corp.
6175 Lusk Blvd.
San Diego, CA 92121
USA
PHONE +1-858-410-5200
FAX +1-858-410-5161
E-MAIL corpcom@allp.com
ONLINE www.allp.com
spacer
 Further Reading:
  News & More:
IMCOR Pharmaceutical Co., Alliance Pharmaceutical Corp., Molecular Biosystems, Inc. and GE Healthcare Ltd., Inc. Enter Into Cross-Licensing Agreement for Ultrasound Contrast PatentsOpen this link in a new window
   by www.prnewswire.com    
BG1135InfoSheet: - Contrast Agents - Intro, Historical Development, Microbubbles, etc.MRI Resource Directory: - Contrast Agents -
 
From Bracco Research S. A., Geneva, Switzerland
BG1135 is a polymer-shelled new ultrasound contrast agent under development. The air-filled microsphere has a rigid, 100 nm thick polymeric shell and a mean diameter of 2.9 mm with 99% less than 8 mm.
The destruction mechanism of BG1135 is unique among microbubbles. The microbubbles of BG1135 appear to acquire a small shell defect, allowing the filling gas to stream out and creating a new gas bubble, but leaving the old shell intact. No significant differences between the diameters of the shells can be measured before and after insonation even though the agent is fragmented.

Drug Information and Specification:
RESEARCH NAME BG1135
DEVELOPER Bracco Diagnostics, Inc.
DEVELOPMENT STAGE Preclinical
APPLICATION Intravenous
TYPE Microbubble
SHELL Polymer
GAS Air
MICROBUBBLE SIZE Mean diameter: 2.9 µm
99% < 8µm
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer
 Further Reading:
  Basics:
Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agentsOpen this link in a new window
   by escholarship.org    
US Resources  
Ultrasound Guided Interventions - Used and Refurbished UltraSound Equipment - Hospitals - Safety - UltraSound Technician and Technologist Jobs - Gynecology
 
     1 - 5 (of 24)     next
Result Pages : [1]  [2]  [3 4 5]
 Random Page
 
US-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  


Look
      Ups



UltraSound - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2006 - 2010 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertising
 [last update: 2010-09-07 06:10:53]